Suggested remit: To appraise the clinical and cost effectiveness of pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6397
Provisional Schedule
- Committee meeting:
- 06 October 2026
- Expected publication:
- 24 February 2027
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
Stakeholders
- Companies sponsors
- Eli Lilly (pirtobrutinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Cancer UK
- Leukaemia Care
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- UK CLL Forum
- Associated public health groups
- None
- Comparator companies
- AbbVie (venetoclax) (confidentiality agreement signed, participating)
- AstraZeneca UK (acalabrutinib) (confidentiality agreement signed, participating)
- BeOne Medicines UK (zanubrutinib) (confidentiality agreement signed, participating)
- Johnson & Johnson Innovative Medicine (ibrutinib) (confidentiality agreement not signed, not participating)
- Roche (obinutuzumab, rituximab) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 March 2026 | Invitation to participate |
| 14 January 2026 - 11 February 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 14 October 2024 | Note - Note added to the project documents |
| 08 August 2024 | Note - Note added to the project documents |
| 14 February 2024 | In progress. Scoping commenced. |
| 30 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 January 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual